Compare
Propanc Biopharma, Inc. vs Jyong Biotech Ltd. vs Clene Inc. vs Emmaus Life Sciences, Inc.
| Latest fiscal year | Propanc Biopharma, Inc. PPCB | Jyong Biotech Ltd. MENS | Clene Inc. CLNN | Emmaus Life Sciences, Inc. EMMA |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $200.0K | $12.45M |
| Revenue growth (YoY) | n/a | n/a | -41.5% | -25.2% |
| Gross margin | n/a | n/a | 78.5% (computed) | 93.1% |
| Operating margin | n/a | n/a | n/m | 1.9% |
| Net margin | n/a | n/a | n/m | -60.2% |
| Net income | -$18.86M | -$4.67M | -$26.17M | -$7.49M |
| EPS (Diluted) | -$17.62 | -$0.06 | n/a | -$0.12 |
| Operating cash flow | -$5.68M | -$3.04M | -$18.55M | -$11.0K |
| Free cash flow | -$5.69M | n/a | -$18.59M | -$12.0K |
| Cash & equivalents | n/a | n/a | $5.19M | $2.13M |
| Total assets | $12.78M | $20.78M | $18.13M | $21.44M |
| Total liabilities | $3.38M | $45.68M | $35.72M | $85.04M |
| Shareholders' equity | $9.40M | -$24.91M | -$17.59M | -$63.61M |
| Return on year-end equity | -200.6% | n/a | n/a | n/a |
| Shares outstanding | 3.31M | 76.03M | 10.85M | 70.19M |
Revenue, most recent five fiscal years
| Fiscal year | Propanc Biopharma, Inc. | Jyong Biotech Ltd. | Clene Inc. | Emmaus Life Sciences, Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | $200.0K Ended 2025-12-31 | $12.45M Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | $342.0K Ended 2024-12-31 | $16.65M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $654.0K Ended 2023-12-31 | $29.60M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $473.0K Ended 2022-12-31 | $18.39M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $723.0K Ended 2021-12-31 | $20.61M Ended 2021-12-31 |